84 related articles for article (PubMed ID: 25319888)
21. Unligated epidermal growth factor receptor forms higher order oligomers within microclusters on A431 cells that are sensitive to tyrosine kinase inhibitor binding.
Clayton AH; Tavarnesi ML; Johns TG
Biochemistry; 2007 Apr; 46(15):4589-97. PubMed ID: 17381163
[TBL] [Abstract][Full Text] [Related]
22. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
23. Reversible dimerization of EGFR revealed by single-molecule fluorescence imaging using quantum dots.
Kawashima N; Nakayama K; Itoh K; Itoh T; Ishikawa M; Biju V
Chemistry; 2010 Jan; 16(4):1186-92. PubMed ID: 20024999
[TBL] [Abstract][Full Text] [Related]
24. Her4 and Her2/neu tyrosine kinase domains dimerize and activate in a reconstituted in vitro system.
Monsey J; Shen W; Schlesinger P; Bose R
J Biol Chem; 2010 Mar; 285(10):7035-44. PubMed ID: 20022944
[TBL] [Abstract][Full Text] [Related]
25. Erlotinib antitumor activity in non-small cell lung cancer models is independent of HER1 and HER2 overexpression.
Friess T; Scheuer W; Hasmann M
Anticancer Res; 2006; 26(5A):3505-12. PubMed ID: 17094474
[TBL] [Abstract][Full Text] [Related]
26. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
[TBL] [Abstract][Full Text] [Related]
27. Evidence for extended YFP-EGFR dimers in the absence of ligand on the surface of living cells.
Kozer N; Henderson C; Jackson JT; Nice EC; Burgess AW; Clayton AH
Phys Biol; 2011 Dec; 8(6):066002. PubMed ID: 21946082
[TBL] [Abstract][Full Text] [Related]
28. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
[TBL] [Abstract][Full Text] [Related]
29. Erlotinib directly inhibits HER2 kinase activation and downstream signaling events in intact cells lacking epidermal growth factor receptor expression.
Schaefer G; Shao L; Totpal K; Akita RW
Cancer Res; 2007 Feb; 67(3):1228-38. PubMed ID: 17283159
[TBL] [Abstract][Full Text] [Related]
30. Differential and synergistic effects of epidermal growth factor receptor antibodies on unliganded ErbB dimers and oligomers.
Kozer N; Kelly MP; Orchard S; Burgess AW; Scott AM; Clayton AH
Biochemistry; 2011 May; 50(18):3581-90. PubMed ID: 21495621
[TBL] [Abstract][Full Text] [Related]
31. Analysis of changes in phosphorylation of receptor tyrosine kinases: antibody arrays.
Rani S; O'Driscoll L
Methods Mol Biol; 2015; 1233():15-23. PubMed ID: 25319885
[TBL] [Abstract][Full Text] [Related]
32. Pan-HER, an Antibody Mixture Simultaneously Targeting EGFR, HER2, and HER3, Effectively Overcomes Tumor Heterogeneity and Plasticity.
Jacobsen HJ; Poulsen TT; Dahlman A; Kjær I; Koefoed K; Sen JW; Weilguny D; Bjerregaard B; Andersen CR; Horak ID; Pedersen MW; Kragh M; Lantto J
Clin Cancer Res; 2015 Sep; 21(18):4110-22. PubMed ID: 25908781
[TBL] [Abstract][Full Text] [Related]
33. Quantification of HER1, HER2 and HER3 by time-resolved Förster resonance energy transfer in FFPE triple-negative breast cancer samples.
Ho-Pun-Cheung A; Bazin H; Boissière-Michot F; Mollevi C; Simony-Lafontaine J; Landas E; Bleuse JP; Chardès T; Prost JF; Pèlegrin A; Jacot W; Mathis G; Lopez-Crapez E
Br J Cancer; 2020 Feb; 122(3):397-404. PubMed ID: 31792349
[TBL] [Abstract][Full Text] [Related]
34. The Dipole Potential Modifies the Clustering and Ligand Binding Affinity of ErbB Proteins and Their Signaling Efficiency.
Kovács T; Batta G; Hajdu T; Szabó Á; Váradi T; Zákány F; Csomós I; Szöllősi J; Nagy P
Sci Rep; 2016 Oct; 6():35850. PubMed ID: 27775011
[TBL] [Abstract][Full Text] [Related]
35. Cancer Immunotherapy: More Is (Much) Better.
Yarden Y; Sela M
Clin Cancer Res; 2015 Sep; 21(18):4030-2. PubMed ID: 26019173
[TBL] [Abstract][Full Text] [Related]
36.
Das AA; Jacob E
J Biosci; 2018 Jun; 43(2):295-306. PubMed ID: 29872018
[TBL] [Abstract][Full Text] [Related]
37. HER3 mRNA as a predictive biomarker in anticancer therapy.
Amler LC
Expert Opin Biol Ther; 2010 Sep; 10(9):1343-55. PubMed ID: 20695834
[TBL] [Abstract][Full Text] [Related]
38. Investigation of the dimerization of proteins from the epidermal growth factor receptor family by single wavelength fluorescence cross-correlation spectroscopy.
Liu P; Sudhaharan T; Koh RM; Hwang LC; Ahmed S; Maruyama IN; Wohland T
Biophys J; 2007 Jul; 93(2):684-98. PubMed ID: 17468161
[TBL] [Abstract][Full Text] [Related]
39. EGFR forms ligand-independent oligomers that are distinct from the active state.
Byrne PO; Hristova K; Leahy DJ
J Biol Chem; 2020 Sep; 295(38):13353-13362. PubMed ID: 32727847
[TBL] [Abstract][Full Text] [Related]
40. Assessment of EGFR/HER2 dimerization by FRET-FLIM utilizing Alexa-conjugated secondary antibodies in relation to targeted therapies in cancers.
Waterhouse BR; Gijsen M; Barber PR; Tullis ID; Vojnovic B; Kong A
Oncotarget; 2011 Sep; 2(9):728-36. PubMed ID: 21908901
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
